Parkinson's medication shows promise in treating treatment-resistant depression
· Medical Xpressby Tove Smeds, Lund University
edited by Lisa Lock, reviewed by Robert Egan
Lisa Lock
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Associate Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
For many people who suffer from depression, the condition is not just about feeling down but also about a loss of motivation and difficulty finding pleasure in activities they used to enjoy. A new study conducted in Sweden shows that a medicine used to treat Parkinson's disease can be used as an add-on therapy to alleviate these symptoms in some patients with treatment-resistant depression. The study has been published in Nature Medicine.
The researchers at Lund University and the psychiatric services in Region Skåne have identified the potential new therapy for the condition associated with depression that involves a reduced ability to feel joy, pleasure or motivation—known as anhedonia. Those affected may lose interest in things that they previously found meaningful or rewarding.
The study is an example of what is known as drug repurposing, whereby an already approved medicine is used to treat a different condition. In this study, the researchers investigated pramipexole, which has long been used to treat Parkinson's disease, as an add-on therapy for depression with marked anhedonia.
"Anhedonia is one of the most debilitating symptoms of depression, and something on which current antidepressant therapies often have only a limited effect. Our findings suggest that pramipexole could be an important new therapy option for this patient group," says Daniel Lindqvist, a researcher at Lund University and senior consultant in psychiatry at Region Skåne.
How the trial worked
All participants in the study had marked anhedonia. Patients were given either pramipexole or a placebo as an add-on to their ongoing medication for nine weeks.
"Those treated with pramipexole for anhedonia showed a more pronounced improvement compared with the placebo group. The effect persisted during a six-month follow-up period among those patients who chose to continue treatment," Lindqvist says.
The researchers used advanced brain imaging techniques (7 Tesla fMRI) to investigate the possible biological mechanisms underlying the effect, and activity monitors to assess whether the therapy affected patients' everyday movement and activity levels.
"We found that pramipexole was linked to a positive effect on the brain's reward system and increased physical activity in everyday life. This supports the theory that the drug affects the dopamine system, which plays a key role in motivation and reward processing," says Filip Ventorp, a postdoctoral researcher at Lund University and resident physician at Region Skåne.
Side effects and follow-up
Most patients experienced no major issues with the treatment, and few dropped out during the randomized controlled trial. Common side effects included sleep problems, nausea and dizziness, but these could usually be managed by adjusting the dose. Even those who chose to continue in the follow-up phase of the study for a further six months generally responded well to the therapy.
"Efficacy and safety were maintained over time during the follow-up phase, which is particularly relevant in cases of long-term and treatment-resistant depression. Although most participants in our study tolerated the drug well, it is important to monitor any side effects, such as impaired impulse control and daytime fatigue," says Marie Asp, a psychiatric researcher at Lund University and senior consultant in psychiatry at Region Skåne.
Publication details
Filip Ventorp et al, Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial, Nature Medicine (2026). DOI: 10.1038/s41591-026-04465-9
Journal information: Nature Medicine
Key medical concepts
Clinical categories
PsychiatryPsychology & Mental health Provided by Lund University Who's behind this story?
Lisa Lock
BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Parkinson's medication shows promise in treating treatment-resistant depression (2026, June 12) retrieved 12 June 2026 from https://medicalxpress.com/news/2026-06-parkinson-medication-treatment-resistant-depression.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.